

REMARKS

Claim 39-45 were withdrawn from consideration. Examiner indicated that claims 39-46 were withdrawn from consideration. However, Claim 46, directed toward pharmaceutical composition, was not withdrawn from consideration. Applicants elected Group II directed to compound or composition. Applicants ask that the Examiner indicates the status of this specific claim. Examiner has indicated that the rejoinder of withdrawn claims would require further consideration and/or search. Applicants therefore cancelled the withdrawn claims 39-45.

Examiner has indicated that claims 28, 31-38 and 50 are allowed.

Conclusion

Applicants have addressed each and every issue set forth by the Examiner. Applicants respectfully submit that the present application is in good condition for allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-5027.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 50-4409 for any additional fees under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Respectfully submitted,

Novartis Institutes for Biomedical Research
NIBR Patents
220 Massachusetts Ave.
Cambridge, MA 02139
(617) 871-5027

/Sophie Binet Cross/
Sophie Binet Cross
Agent for Applicant
Reg. No. 59,494

Date: August 31, 2009